Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-cash Items (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Non-cash Items for 10 consecutive years, with $706000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 98.88% to $706000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $706000.0 through Dec 2025, down 98.88% year-over-year, with the annual reading at $706000.0 for FY2025, 98.88% down from the prior year.
  • Non-cash Items hit $706000.0 in Q4 2025 for Rocket Pharmaceuticals, down from $9.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $349.4 million in Q1 2021 to a low of $706000.0 in Q4 2025.
  • Historically, Non-cash Items has averaged $127.5 million across 5 years, with a median of $111.7 million in 2022.
  • Biggest five-year swings in Non-cash Items: surged 333.28% in 2021 and later crashed 98.88% in 2025.
  • Year by year, Non-cash Items stood at $128.8 million in 2021, then decreased by 7.8% to $118.8 million in 2022, then skyrocketed by 111.0% to $250.6 million in 2023, then plummeted by 74.74% to $63.3 million in 2024, then plummeted by 98.88% to $706000.0 in 2025.
  • Business Quant data shows Non-cash Items for RCKT at $706000.0 in Q4 2025, $9.9 million in Q3 2025, and $6.5 million in Q2 2025.